Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.
Boston University Psychiatry Research Center, Clinical Studies Unit, Boston, Massachusetts, United States
AP-HP Cochin, Paris, France
Chiba University Hospital, Chiba, Japan
MidAtlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
Ep0060 005, Dallas, Texas, United States
Ep0060 503, Messina, Italy
Ep0060 221, Kiev, Ukraine
Sp1042 654, Biel, Switzerland
Sp1042 625, Odesa, Ukraine
Sp1042 340, Katowice, Poland
Sp0967 537, Shenzhen, China
Sp0967 542, Athens, Greece
Sp0967 456, Nizhny Novgorod, Russian Federation
University Hospital, London, Ontario, Canada
Bezirkskrankenhaus Augsburg, Augsburg, Germany
Krankenhaus Hedwigshöhe, Berlin, Germany
Hannover Medical School, Hannover, Germany
Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.